Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET Alterations

NCT05675605 is registered in ClinicalTrials.gov with TYK Medicines, Inc as lead sponsor.

NCT NCT05675605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05675605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET Alterations
Lead sponsor
TYK Medicines, Inc
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 24, 2023
Completion date
December 1, 2025
Enrollment
248 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer, neoplasms, ret-altered non small cell lung cancer, ret-altered papillary thyroid cancer